$HURA News

TuHURA Reports Early Responses in Deep-Seated Merkel Cell Cancer Study

TuHURA Biosciences Provides First Look at Data from its Open-Label Study of IFx-2.0 as an Adjunctive Therapy to Keytruda® in First Line Treatment of Patients with Deep Seated Metastatic Merkel Cell Carcinoma

TuHURA Reports Initial Data Showing Partial Responses In First Three Metastatic Merkel Cell Carcinoma Patients Treated With Ifx-2.0 Plus Keytruda

TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025

TuHURA Biosciences Secures US Patent For TBS-2025, Entitled ‘Anti-VISTA Antibodies And Uses Thereof’

TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology

TuHURA Biosciences Receives U.S. Patent For Administration Of DOR Antagonists

TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers

FDA Gives Clearance To TuHURA Biosciences' IND Application For TBS-2025 VISTA-Inhibiting Antibody For Molecularly Defined Subsets Of AML And Other Blood-Related Cancers

TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

HURA: Milestone Progression Over Next 12 Months

TuHURA Biosciences, Inc. (HURA) Shareholder/Analyst Call Prepared Remarks Transcript

Citizens Reiterates Market Outperform on TuHURA Biosciences, Maintains $9 Price Target

TuHURA Biosciences Highlights Phase III IFx Push, AML Trial Plans at Canaccord

TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

TuHURA Biosciences Q2 EPS $(0.14) Beats $(0.15) Estimate

TuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference

TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers

TuHURA Biosciences Submits Investigational New Drug Application With FDA For Trial Of Its TBS-2025 VISTA Antibody To Treat Molecularly Defined Subsets Of Acute Myeloid Leukemia

HURA: Refining TBS-2025 Development Plan